City Therapeutics
Jingxuan Liu possesses extensive experience in the pharmaceutical and biotechnology sectors, currently serving as the Senior Director of Biology at City Therapeutics. Previously, Jingxuan held the position of Director for Discovery Biology and Pharmacology at ReNAgade Therapeutics. Prior roles also include Associate Director of Immunology Translational Science and Medicine at The Janssen Pharmaceutical Companies of Johnson & Johnson and Associate Director at Momenta Pharmaceuticals. This professional background highlights a strong expertise in biology and pharmacology within the context of drug development.
This person is not in any teams
This person is not in any offices
City Therapeutics
Founded by pioneering executives and scientists in RNAi, City Therapeutics is advancing next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to improve and expand the reach of RNAi-based medicines. City’s mission is to build the leading next-generation RNAi therapeutics company, unlocking RNAi’s transformative potential to help patients with a wide range of diseases.